A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: Report of a Japan Clinical Oncology Group trial (JCOG 9606)

British Journal of Cancer

Volumn 103, Issue 1, 2010, Pages 6-11

  Kunitoh, H ^a,j   Tamura, T ^a   Shibata, T ^b   Takeda, K ^c   Katakami, N ^d   Nakagawa, K ^e   Yokoyama, A ^f   Nishiwaki, Y ^g   Noda, K ^h   Watanabe, K ⁱ   Saijo, N ^e,g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Niigata Cancer Center   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h KANAGAWA CANCER CENTER   (Japan)

ⁱ YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^j MITSUI MEMORIAL HOSPITAL   (Japan)

more..

Author keywords

chemotherapy; dose dense; radiotherapy; surgical resection; thymoma; unresectable

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE APLASIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION INJURY; THORACOTOMY; THORAX SURGERY; THYMOMA; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THYMOMA; THYMUS NEOPLASMS;

EID: 77954175701     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605731     Document Type: Article

References (31)

1. Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, Ardissone F, Brizzi MP, Dolcetti A, Dogliotti L (1999) Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclopho-sphamide in locally advanced thymomas: a single institution experience. Br J Cancer 81: 841-845
2. Ciernik IF, Meier U, Lutolf UM (1994) Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. J Clin Oncol 12: 1484-1490
3. Curran Jr WJ, Kornstein MJ, Brooks JJ, Turrisi III AT (1988) Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6: 1722-1727
4. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas Jr CR (2004) Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59: 654-664
5. Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, Kusunoki Y, Takada M, Kawahara M, Ogawara M, Kodama N, Kubota K, Furuse K (1997) CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75: 306-309
6. Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N (1998) Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 16: 2126-2132
7. Giaccone G (2005) Treatment of malignant thymoma. Curr Opin Oncol 17: 140-146
8. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14: 814-820
9. Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P (2009) Thymoma: a focus on current therapeutic management. J Thorac Oncol 4: 119-126
10. Goldie JH, Coldman AJ (1983) Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923-931
11. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44: 369-379
12. Kunitoh H, Tamura T, Shibata T, Nakagawa K, Takeda K, Nishiwaki Y, Osaki Y, Noda K, Yokoyama A, Saijo N (2009) A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer 101: 1549-1554
13. Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756-767
14. Liu HC, Chen YJ, Tzen CY, Huang CJ, Chang CC, Huang WC (2006) Debulking surgery for advanced thymoma. Eur J Surg Oncol 32: 1000-1005
15. Loehrer Sr PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15: 3093-3099
16. Loehrer Sr PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas Jr CR, Livingston R, Johnson DH (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91: 2010-2015
17. Loehrer Sr PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12: 1164-1168
18. Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, Angeletti CA, Mussi A (2006) Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol 1: 308-313
19. Mangi AA, Wain JC, Donahue DM, Grillo HC, Mathisen DJ, Wright CD (2005) Adjuvant radiation of stage III thymoma: is it necessary? Ann Thorac Surg 79: 1834-1839
20. Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492
21. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
22. Murray N (1987) The importance of dose and dose intensity in lung cancer chemotherapy. Semin Oncol 14: 20-28
23. Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N (1991) Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9: 1632-1638
24. Ogawa K, Uno T, Toita T, Onishi H, Yoshida H, Kakinohana Y, Adachi G, Itami J, Ito H, Murayama S (2002) Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer 94: 1405-1413
25. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A (2002) The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94: 624-632
26. Regnard JF, Magdeleinat P, Dromer C, Dulmet E, de Montpreville V, Levi JF, Levasseur P (1996) Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 112: 376-384
27. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22: 1501-1509
28. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M, Suemasu K (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23: 250-257
29. Travis WB, Brambilla E, Muller-Hermelinck HK, Harris CC (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon
30. Urgesi A, Monetti U, Rossi G, Ricardi U, Casadio C (1990) Role of radiation therapy in locally advanced thymoma. Radiother Oncol 19: 273-280
31. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, Miyazawa N (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2: 73-78